Loading...
Market
What will be the primary distribution channel for BEYFORTUS® in the US by the end of 2024?
2
Resolution / Starting Odds
Hospitals • 25%
Pharmacies • 25%
Clinics • 25%
Online • 25%
Sales data from Sanofi and AstraZeneca segmented by distribution channel
Story
Sanofi and AstraZeneca Win FDA Approval for BEYFORTUS® Manufacturing Line to Protect Babies
Sep 16, 2024, 05:00 PM
Sanofi and AstraZeneca have received approval from the U.S. Food and Drug Administration (FDA) for a manufacturing line dedicated to their preventive respiratory syncytial virus (RSV) therapy. The approval allows Sanofi to begin shipping BEYFORTUS® in the United States, aimed at protecting babies against RSV disease. This development marks a significant step for both companies in their efforts to combat RSV.
View original story
Similar markets
Online Retailers • 25%
Pharmacy Chains • 25%
Healthcare Providers • 25%
Other • 25%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
Pharmacies • 25%
Online retailers • 25%
Healthcare providers • 25%
Other • 25%
Global Fund • 25%
PEPFAR • 25%
Gilead Sciences • 25%
Other • 25%
Yes • 50%
No • 50%
Mostly in the US • 25%
Mostly in Europe • 25%
Mostly in Asia • 25%
Evenly distributed globally • 25%
Pfizer • 25%
Roche • 25%
Novo Nordisk • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Other • 25%
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
CVS • 25%
UNH • 25%
CI • 25%
Other • 25%
Walmart • 25%
CVS • 25%
Walgreens • 25%
Amazon • 25%